Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$706.74 USD

706.74
579,002

-2.75 (-0.39%)

Updated Aug 6, 2025 02:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PacBio's (PACB) New Solution to Boost Public Health Protection

by Zacks Equity Research

PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.

Zacks Equity Research

Veeva Systems (VEEV) Vault Quality Suite Gets Adopted by CBM

by Zacks Equity Research

Veeva Systems' (VEEV) product gets adopted by CBM. This can drive the development and delivery of groundbreaking treatments for patients.

Zacks Equity Research

Baxter's (BAX) $100M Investment to Strengthen Global Presence

by Zacks Equity Research

Baxter's (BAX) strategic investment to help expand the manufacturing footprint of BPS and ensure improvement in products.

Zacks Equity Research

Here's Why You Should Invest in West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for McKesson (MCK) Stock

by Zacks Equity Research

McKesson (MCK) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

McKesson (MCK) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

McKesson's (MCK) fiscal second-quarter 2022 results benefit from substantial growth in the Medical-Surgical Solutions business.

Zacks Equity Research

McKesson (MCK) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of 31.69% and 6.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate McKesson (MCK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

McKesson (MCK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

Zacks Equity Research

Veeva Systems' (VEEV) eConsent Solution Gets Adopted by Celerion

by Zacks Equity Research

Veeva Systems' (VEEV) solution gets adopted by Celerion in a bid to boost paperless clinical trials.

Zacks Equity Research

Here's Why You Should Add STERIS (STE) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to elevated consumer demand and rebound in procedure volumes and raised 2022 outlook.

Zacks Equity Research

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.

Zacks Equity Research

Hill-Rom (HRC) New LT Strategy Aids, Y/Y Comparisons Ail

by Zacks Equity Research

Hill-Rom's (HRC) newly initiated long-term growth strategies through fiscal 2022, focusing on all four strategic priorities, look attractive at this moment.

Zacks Equity Research

Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on strong demand for NexSys PCS system and potential of Hemostasis Management franchise.

Zacks Equity Research

Here's Why You Should Invest in AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.

Zacks Equity Research

Henry Schein (HSIC) Dental Sales Grow Globally Despite Pandemic

by Zacks Equity Research

Widespread network and channel mix along with favorable long-term trends in the dental business bode well for Henry Schein (HSIC).

Zacks Equity Research

Haemonetics (HAE) Rides on Plasma Arm Recovery Amid COVID Woes

by Zacks Equity Research

Haemonetics' (HAE) hospital business is recovering primarily driven by continued improvement in hospital procedures.

Zacks Equity Research

Here's Why You Should Invest in West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

Zacks Equity Research

Accuray's (ARAY) Radiotherapy Technologies Adopted by Unicancer

by Zacks Equity Research

Accuray's (ARAY) proprietary radiotherapy technologies get selected by Unicancer, which is the largest network of comprehensive cancer centers in Europe.

Zacks Equity Research

QIAGEN (QGEN) to Boost NeuMoDx Production With US DOD Contract

by Zacks Equity Research

QIAGEN's (QGEN) NeuMoDx platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics testing, including laboratory-developed tests.

Zacks Equity Research

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.

Sheraz Mian headshot

Making Sense of the Q3 Earnings Picture and Beyond

by Sheraz Mian

Recent updates on the revisions trends have been somewhat disconcerting, as you can see in the chart below that tracks the evolution of Q3 earnings growth expectations...

Zacks Equity Research

McKesson (MCK) Up 3.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.